Pharnext adds industry veteran to board
December 10, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Michel de Rosen, pharnext
France-based clinical stage biopharma firm Pharnext has appointed Michel de Rosen to its board of directors. For nearly 25 years …
AstraZeneca constipation drug gets EU nod
December 9, 2014Sales and Marketing AstraZeneca, KODIAC, NKTR-118, PAMORA, moventig, naloxegol
AstraZeneca’s opioid-induced constipation drug Moventig has been approved by the European Commission. The first once-daily PAMORA tablet to be given …
NICE U-turn over Janssen arthritis drug
December 9, 2014Sales and Marketing Janssen, NHS, NICE, Stelara, arthritis, ustekinumab
NICE has reversed its decision on Janssen’s Stelara and is now recommending the active psoriatic arthritis drug. The pricing watchdog …
Mixed results for new leukaemia drugs
December 9, 2014Research and Development, Sales and Marketing AML, Bayer, Nexavar, Qinprenzo, Sunesis Pharmaceuticals, sorafenib
Two trials of new drugs for acute myeloid leukaemia (AML) have shown promising results in younger and older groups of …
Novartis biosimilar rivals Amgen offering
December 9, 2014Sales and Marketing Amgen, Neupogen, Novartis, Sandoz, filgrastim, zarzio
An investigational biosimilar by Novartis’ generic pharma arm Sandoz has been found to have comparable safety and efficacy readings to …
Ranbaxy and Sun Pharma merger approved
December 9, 2014Manufacturing and Production, Sales and Marketing FDA, Ranbaxy, Sun Pharma, cci, tamsulosin, tolterodine
The Competition Commission of India (CCI) has approved Sun Pharma’s acquisition of struggling drugmaker Ranbaxy, subject to conditions designed to …
Pfizer buys into gene therapy
December 9, 2014Research and Development, Sales and Marketing London, Pfizer, gene therapy, haemophilia, spark, therapeutics
Pfizer has announced that it is establishing a gene therapy platform as it looks to expand its rare diseases operations. …
Celgene appoints new UK general manager
December 9, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Wim Souverijns
Celgene has appointed Wim Souverijns as its new vice president and general manager for UK and Ireland. Souverijns (pictured) takes …
AZ triumphs in Nexium pay-for-delay trial
December 8, 2014Sales and Marketing AstraZeneca, Dr Reddy's, Nexium, Ranbaxy, dr reddys, esomeprazole
AstraZeneca and Ranbaxy have avoided what might have been a $10 billion pay out regarding delays to the generic version …
Updated: Merck buys antibiotics specialist Cubist
December 8, 2014Sales and Marketing Antibiotics, Merck, Novartis, cubicin, cubist, eumer
Merck has purchased US antibiotics maker Cubist in a deal valued at $9.5 billion. The acquisition values Cubist at around …
Blackberry creates cancer diagnostic tool
December 8, 2014Medical Communications, Sales and Marketing Blackberry, chen, diagnostic, nanthealth, passport, soon-shiong
Canadian smartphone maker Blackberry is entering the healthcare arena with a cancer diagnostic tool aimed at doctors and nurses. Via …
Merck and Galderma breach ABPI code
December 8, 2014Medical Communications, Sales and Marketing ABPI, Erbitux, Galderma, PMCPA, merch
Merck Serono and Galderma will be named in advertisements as guilty of the most serious breach of the ABPI Code …
Analysis finds no Actos bladder cancer link
December 8, 2014Sales and Marketing Actos, Cancer, Takeda, bladder, lilly, pioglitazone, type 2
A large-scale analysis of patient data has found that pioglitazone, the diabetes drug that is the subject of ongoing safety …
The valuable world of Real World Evidence
December 8, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing clinical trials, data, martin goldman, real world evidence, transparency
What do you believe? Are you a doubting Thomas, always wanting to have the pragmatic proof personally presented to you, …
ABPI appoints first manufacturing director
December 8, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, James Christie
The Association of the British Pharmaceutical Industry (ABPI) has appointed James Christie to the newly-created position of project director for …
Bayer files haemophilia drug in EU
December 5, 2014Sales and Marketing BAY 81-8973, Bayer, Biogen IDEC, EMA, elocta, haemophilia a, kogenate
Bayer has submitted a marketing authorisation application to the EMA for its haemophilia A therapy BAY 81-8973. The German firm’s …
GSK cancels sale of established products
December 5, 2014Medical Communications, Sales and Marketing FDA, GSK, Paxil, Seroxat, Zantac, bribery, cuts, imitrex
GlaxoSmithKline has decided not to sell off several of its ageing brands in the face of continuing business problems. The …
Merck sells manufacturing facility to Sanofi
December 5, 2014Manufacturing and Production, Sales and Marketing Merck, Merial, Puerto Rico, Sanofi, manufacturing
Sanofi’s animal health unit Merial is acquiring Merck’s manufacturing facility in Barceloneta, Puerto Rico. The proposed transaction requires the nod …
Ranbaxy launches J&J biosimilar in India
December 5, 2014Manufacturing and Production, Sales and Marketing CHMP, FDA, India, J&J, JJ, Ranbaxy, Remicade, nlem, nppa
Ranbaxy has launched the first biosimilar of Johnson & Johnson’s Remicade (infliximab) in India, marking the firm’s entry into monoclonal …
Speedy FDA nod for Amgen leukaemia drug
December 5, 2014Research and Development, Sales and Marketing B-cell lymphoblasts, FDA, Kyprolis, blinatumomab, blincyto, leukaemia
The FDA has approved Amgen’s Blincyto (blinatumomab) to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukaemia (B-cell ALL). …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
